THERAPY DOSSIER · th-429cda8d62fd

Dextran-isocyanatoethyl methacrylate-ethylamine (DexIEME) self-crosslinkable hydrogel

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28945013 ↗2017Reported benefit

Pro-Regenerative Hydrogel Restores Scarless Skin during Cutaneous Wound Healing.

MouseWoundTopical application to the wound

Model: Acute deep dermal cutaneous wound in murine and porcine models

DexIEME hydrogel showed superior biocompatibility with low proinflammatory response, promoted M2 macrophage phenotype, and produced complete skin regeneration with hair regrowth on pre-existing scars in mice and regenerated skin in deep porcine wounds, while untreated scars remained intact.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…